The 15 most recent market catalysts affecting $RMD, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 15, 2026
Corporate Catalyst
Bullish
Impact 75
ResMed shares are trading higher after RBC Capital upgraded the stock from Sector Perform to Outperform and raised its price target from $244 to $262.
The upgrade of ResMed (RMD) by RBC Capital from 'Sector Perform' to 'Outperform' and the raised price target from $244 to $262 is a significant positive catalyst for the stock. Ana…
Sep 15, 2026
Corporate Catalyst
Bullish
Impact 65
RBC Capital Upgrades ResMed to Outperform, Raises Price Target to $262
RBC Capital's upgrade of ResMed (RMD) to Outperform and the increase in its price target from $244 to $262 indicates a more bullish outlook from a prominent financial institution. …
Sep 1, 2026
Corporate Catalyst
Neutral
Impact 65
ResMed Announces $450M Accelerated Share Repurchase Agreement With Citibank
ResMed announced an Accelerated Share Repurchase (ASR) agreement with Citibank for $450 million of its common stock. This ASR is a component of the company's larger, previously aut…
Aug 31, 2026
Corporate Catalyst
Bullish
Impact 55
Keybanc Maintains Overweight on ResMed, Raises Price Target to $267
Keybanc analyst Brett Fishbin maintained an 'Overweight' rating on ResMed (RMD) and raised the price target from $255 to $267. This action signals continued confidence in ResMed's …
Aug 19, 2026
Corporate Catalyst
Bullish
Impact 65
ResMed shares are trading higher after Rothschild & Co. initiated coverage on the stock with a Neutral rating and announced a $230 price target.
The initiation of coverage by a reputable firm like Rothschild & Co. often brings increased institutional attention and liquidity to a stock, even with a 'Neutral' rating. The anno…
Aug 19, 2026
Corporate Catalyst
Neutral
Impact 55
Rothschild & Co Initiates Coverage On ResMed with Neutral Rating, Announces Price Target of $230
Rothschild & Co's initiation of coverage on ResMed with a Neutral rating and a $230 price target provides a new data point for investors. While not a 'buy' or 'sell' recommendation…
Aug 7, 2026
Corporate Catalyst
Bullish
Impact 55
RBC Capital Maintains Sector Perform on ResMed, Raises Price Target to $244
RBC Capital's analyst Craig Wong-Pan maintained a 'Sector Perform' rating on ResMed (RMD) but raised the price target by $10 to $244. This action signals a slightly improved valuat…
Aug 7, 2026
Corporate Catalyst
Bearish
Impact 75
ResMed shares are trading lower after multiple analyst firms lowered their respective price targets on the stock.
This headline signals a significant negative corporate catalyst for ResMed. Analyst downgrades often reflect a reassessment of a company's fundamentals, competitive landscape, or f…
Aug 7, 2026
Corporate Catalyst
Bearish
Impact 55
Piper Sandler Maintains Neutral on ResMed, Lowers Price Target to $225
Piper Sandler analyst Adam Maeder maintained a 'Neutral' rating on ResMed (RMD) but reduced the price target from $233 to $225. This action signals a slightly diminished valuation …
Aug 7, 2026
Corporate Catalyst
Bearish
Impact 55
Keybanc Maintains Overweight on ResMed, Lowers Price Target to $255
Keybanc analyst Brett Fishbin maintained an 'Overweight' rating on ResMed, signaling a continued positive long-term outlook for the company. However, the price target was slightly …
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 55
Resmed Raises Quarterly Dividend From $0.60 To $0.66/Share
Resmed's decision to raise its quarterly dividend by 10% from $0.60 to $0.66 per share is a positive corporate catalyst. This move typically indicates robust cash flow, strong prof…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 75
ResMed Q4 Adj. EPS $2.95 Beats $2.89 Estimate, Sales $1.464B Beat $1.459B Estimate
ResMed (RMD) announced Q4 adjusted EPS of $2.95, surpassing the $2.89 consensus estimate by 2.08%, and sales of $1.464 billion, beating the $1.459 billion estimate by 0.32%. This r…
Jul 15, 2026
Corporate Catalyst
Bearish
Impact 55
Mizuho Maintains Outperform on ResMed, Lowers Price Target to $220
Mizuho analyst Anthony Petrone maintained an 'Outperform' rating on ResMed, signaling continued confidence in the company's long-term prospects. However, the decision to lower the …
Jul 13, 2026
Corporate Catalyst
Bearish
Impact 75
ResMed shares are trading lower after Citigroup downgraded the stock from Buy to Neutral rating and lowered its price target from $270 to $235.
The downgrade of ResMed by Citigroup from Buy to Neutral, coupled with a substantial price target reduction, is a significant negative catalyst for the stock. Analyst downgrades fr…
Jul 13, 2026
Corporate Catalyst
Bearish
Impact 65
Citigroup Downgrades ResMed to Neutral, Lowers Price Target to $235
Citigroup analyst Laura Sutcliffe downgraded ResMed (RMD) from a 'Buy' to a 'Neutral' rating and lowered the price target from $270 to $235. This action signals a less optimistic v…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.